# Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis

> **NCT06517875** · PHASE2 · RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 68 (estimated)

## Conditions studied

- Primary Myelofibrosis
- Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis

## Interventions

- **DRUG:** Momelotinib
- **DRUG:** Luspatercept

## Key facts

- **NCT ID:** NCT06517875
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-28
- **Primary completion:** 2027-03-19
- **Final completion:** 2028-03-17
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06517875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06517875, "Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06517875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*